Skip to main content

MS (Multiple Sclerosis)

Neuro-Inflammatory Service

COVID-19: Information for patients

Welcome to the neuro-inflammatory service webpages. Please find below information on how the service is running due to the ongoing  COVID-19 pandemic, as well as information for you if you are on DMT’s (Disease Modifying Therapies)

We shall do our best to keep these pages up to date but if the information here (or on the MS Society and MS Trust website) don’t answer your question please leave us a message on our helpline, 02920 745018

Our Helpline is manned on the weekdays, but as usual it is not an emergency service. Please remember to speak slowly and clearly and leave one message, with your name, date of birth and a summary of your question so we can get the most suitable person to reply to you as soon as possible.

COVID vaccines and MS Q&A

The latest survey by the UK MS Register has shown that almost 70% of people living with MS would have the COVID-19 vaccine, but as many as 3 in 4 said they want more advice: MS Society Information

To help answer questions and alleviate concerns, MS Society Cymru is hosting a live online Q&A via zoom;

26th February 2021 at 12:15pm 

Taking part in the Q&A will be neurologists Dr Emma Tallantyre (University Hospital Wales, Cardiff), Dr Gillian Ingram (Swansea Bay UHB) and Dr Katharine Harding (Aneurin Bevan UHB).

To register for the webinar, please follow the link below;
Webinar Registration 


To protect patients and staff, many of our routine appointments have been changed to telephone or video consultations for the foreseeable future.

Some urgent consultations are taking place face to face at Rookwood Hospital, following strict safety guidelines (with staff wearing PPE and attendees wearing masks and having symptoms and temperature checked at the door)

Infusions are now taking place in Suite 16 of the UHW outpatient department (again following safety guidelines)

For blood monitoring please see separate section

The FAQ's below provide further information for patients.
Follow us: